<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Vigabatrin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01080</strong>&#160; (APRD00282)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An analogue of gamma-aminobutyric acid, vigabatrin is an irreversible inhibitor of 4-aminobutyrate transaminase, the enzyme responsible for the catabolism of gamma-aminobutyric acid. (From Martindale The Extra Pharmacopoeia, 31st ed). Off-label uses include treatment of cocaine dependence.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01080/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01080/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01080.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01080.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01080.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01080.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01080.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01080">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>gamma-Vinyl GABA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>GVG</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vigabatrin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN</td></tr><tr><td>Vigabatrina</td><td>Spanish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vigabatrine</td><td>French</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vigabatrinum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Sabril</td><td>Lundbeck Inc. </td></tr><tr><td>Sabrilan </td><td>Lundbeck Inc. </td></tr><tr><td>Sabrilex </td><td>Lundbeck Inc. </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/gaba-agents">GABA Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>60643-86-9</td></tr><tr><th>Weight</th><td>Average: 129.157<br>Monoisotopic: 129.078978601</td></tr><tr><th>Chemical Formula</th><td>C<sub>6</sub>H<sub>11</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>PJDFLNIOAUIZSL-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-aminohex-5-enoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC(CCC(O)=O)C=C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Gamma Amino Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Amino Fatty Acids; Unsaturated Fatty Acids; Polyamines; Carboxylic Acids; Enolates; Monoalkylamines</td></tr><tr><th>Substituents</th><td>carboxylic acid; enolate; polyamine; primary amine; amine; primary aliphatic amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use as an adjunct in treatment resistant epilepsy, refractory complex partial seizures, and secondary generalized seizures. It is also used as monotherapy in infantile spasms in West syndrome.</td></tr><tr><th>Pharmacodynamics</th><td>Vigabatrin is an anticonvulsant chemically unrelated to other anticonvulsants. Vigabatrin prevents the catabolism of GABA by irreversibly inhibiting the enzyme GABA transaminase. It is an analog of GABA, but it is not a receptor agonist. However, vigabatrin is not a potent inhibitor of GABA-T with a Ki of 10 mM. </td></tr><tr><th>Mechanism of action</th><td>Vigabatrin increases brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by irreversibly inhibiting enzymes that catabolize GABA (gamma-aminobutyric acid transaminase, GABA-T). Duration of action is determined by rate of GABA-T re-synthesis. Vigabatrin may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. </td></tr><tr><th>Absorption</th><td>Rapidly absorbed following oral administration, absorption is comparable between neonates, infants, and children. 
Cmax, 50 mg/kg dose, neonates= 14 mg/L;
Tmax, 50 mg/kg dose, neonates = 2.1 hours;
However, extent of absorption is higher and elimination half life is longer in neonates compared to children and infants. This is because neonates have reduced renal function compared to the aforementioned population groups. 
AUC, 50 mg/kg dose, neonates = 142.6 &#177; 44.0 mg/L/hr; 
Food may slightly decrease the rate (Cmax decreased by 33%, Tmax increased to 2 hours), but not the extent of absorption. Furthermore, vigabatrin does not cross the blood-brain-barrier well, thus high doses are needed. 
</td></tr><tr><th>Volume of distribution</th><td><p>1.1 L/kg</p></td></tr><tr><th>Protein binding</th><td>Not protein bound </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Almost no metabolic transformation. Does not induce the hepatic cytochrome P450 system.</p></td></tr><tr><th>Route of elimination</th><td>Eliminated primarily through renal excretion as unchanged drugs (80%).</td></tr><tr><th>Half life</th><td>Neonates, 50 mg/kg = 7.5 &#177; 2.1 hours (due to reduced renal function); 
Infants = 5.7 hours;
Adults = 7.5 hours;
Elderly = 12 - 13 hours


</td></tr><tr><th>Clearance</th><td><p>Infants = 2.4 &#177; 0.8 L/h; <br>
Children = 5.7 &#177; 2.5 L/h</p></td></tr><tr><th>Toxicity</th><td>LD50, oral, rat: 3000 mg/kg; 
Visual field defects may occur following cumulative doses in excess of 2 kg. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9213</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5191</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.797</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.949</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9856</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8944</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8785</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7664</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9149</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9389</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9654</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.963</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9824</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8409
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7678
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.7494
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.6656 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9617
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9772
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Lundbeck inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Oral</td><td>500 mg/packet</td></tr><tr><td>Powder, for suspension</td><td>Oral</td><td>0.5 g/sachet</td></tr><tr><td>Tablet</td><td>Oral</td><td>500 mg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01068">Clonazepam</a></td><td>Vigabatrin increases Cmax of clonazepam by 30% and decreases Tmax by 45% </td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Vigabatrin decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00358">Mefloquine</a></td><td>Mefloquine may decrease the serum concentration of Vigabatrin. This may increase the risk of seizure in patients receiving Vigabatrin to prevent seizures. Consider alternate therapy or monitor for changes in Vigabatrin serum concentration, therapeutic or adverse effects if Mefloquin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Additive CNS depression may occur. Dose adjustments may be required if one agent is added to existing therapy with the other agent. Monitor for increased CNS depression during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Vigabatrin reduces serum concentrations of phenobarbital by 8-16%. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Vigabatrin reduces plasma levels of phenytoin by 16-20% which may be due to induction of CYP2C. Consider dosage adjustment. </td></tr><tr><td><a href="/drugs/DB00203">Sildenafil</a></td><td>Increased anticonvulsant effects of vigabatrin due to pharmacodynamic synergism. Monitor for adverse effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Vigabatrin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00313">Valproic Acid</a></td><td>Vigabatrin reduces serum concentrations of valproic acid by 8%. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>